Tweets
Does CVD mortality risk change after stopping GC in RA?
➡️28078 incident GC users
➡️Incr mortality risk from CVD &infections persists post-cessation
➡️Risk never returns to pre-GC level after prolonged use
⏩Use GC at lowest dose for shortest time possible
Ab2673 #ACR24 @Rheumnow https://t.co/dtLU8obLke
Links:
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 5 months ago
Increased risk of mortality related to negative effects of GC use persists long after stopping and never return to pre-GC levels. #GCStewardship
#ACR24 @RheumNow ABST#2673 https://t.co/5AwHDmvQGf
Jiha Lee @JihaRheum ( View Tweet )
1 year 5 months ago
Ab2674 #ACR24
➡️Most pts starting 1st-line TNFi, who didn't achieve treatment response at 3M, also didn't achieve response from months 3-12
➡️1/4 pts achieving LDA/remission at 3M were no longer in LDA/remission at 12M
@RheumNow https://t.co/pFOo86tJTx
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 5 months ago
Data from the RISE registry show that 9.3% of SLE pts had thrombocytopenia and a smaller percentage with mod-severe TP (2.7%). Severe TP was much rare.
Large data, but well represented grp?
@RheumNow #ACR24 abs2680 https://t.co/Y1Lo9lJGtO
Links:
sheila @RHEUMarampa ( View Tweet )
1 year 5 months ago
An early favorable response to TNFi initiation indicates better long-term success in RA. Assess early and adjust treatment accordingly.
#ACR24 @RheumNow ABST#2674 https://t.co/YTThYiiLpZ
Jiha Lee @JihaRheum ( View Tweet )
1 year 5 months ago
#ACR24 BEST Abstracts from Day 1
The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day.
https://t.co/FHu616Jpyq https://t.co/oKuRcGRRAZ
Dr. John Cush @RheumNow ( View Tweet )
1 year 5 months ago
Would you trust #AI to carry out & read your #USS?
2 systems, ARTHUR & DIANA, were comparable to that of a rheumatologist specialising in MSK US at joint & patient levels
Might this be the future of assessment in rheumatology care?
AbL20 #ACR24 @RheumNow https://t.co/XtnlYafzp4
Mrinalini Dey @DrMiniDey ( View Tweet )
1 year 5 months ago
Nailfold video capillaroscopy (NVC) allows the definite distinction between primary and secondary #Raynaud's phenomenon and can identify early changes such as few giant capillaries &/or microhemorrages
promoting early diagnosis
@RheumNow #ACR24 @rheumarhyme https://t.co/Yl37w6BEZR
sheila @RHEUMarampa ( View Tweet )
1 year 5 months ago
Another + #SLE #RCT - large N
#Dapirolizumab = Peg CD40L + SoC
Vs
#Placebo + SoC
Rapid improvemt
steroid sparing
So what to use in Pts if +Ph3
👇
TYK2 Deucravacitinib
JAKi Upadacitinib
Dapirolizumab
CAR 🚗 Rx
Anifrolimumab
Benlysta
ETC!
#ACRBest L16 @RheumNow #ACR24 https://t.co/wTFucF7BYO
Janet Pope @Janetbirdope ( View Tweet )
1 year 5 months ago
Late breaking abstract L17
CAR-NK Therapy for Refractory SLE.
In a trial of 20 severe SLE patients:
- 75% achieved LLDAS, 50% achieved DORIS remission at 6 months
- B cell reconstitution: 2–3 months post-treatment
- Safety: 2 mild cytokine release syndrome with fever; no severe… https://t.co/MS8cutm48o
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
1 year 5 months ago
The combe-like pattern is observed in pts with APS and also in overlap syndrome
- presence of parallel microthrombi (orange arrow) arranged perpendicularly, hence combe-like
@RheumNow #ACR24 @rheumarhyme https://t.co/IjX7ld9lxW
sheila @RHEUMarampa ( View Tweet )
1 year 5 months ago
The #scleroderma-like pattern on NVC is observed in pts with #dermatomyositis and MCTD
It consists of a combination of giant capillaries, some microhemorrhages, severe capillary loss and angiogenesis
@RheumNow #ACR24 @rheumarhyme https://t.co/WO9BOYn4ir
sheila @RHEUMarampa ( View Tweet )
1 year 5 months ago
